Our Top 5 Microcap Stocks
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel

CNTX Insider Trading

Insider Ownership Percentage: 6.66%
Insider Buying (Last 12 Months): $65,910.00
Insider Selling (Last 12 Months): $0.00

Context Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Context Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Context Therapeutics Share Price & Price History

Current Price: $1.38
Price Change: +0.30 (1.20%)
As of 12/2/2022 10:00 PM ET

This chart shows the closing price history over time for CNTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Context Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/19/2022Martin A. LehrCEOBuy13,000$1.85$24,050.00102,583View SEC Filing Icon  
12/16/2021Martin A. LehrCEOBuy13,000$3.22$41,860.00View SEC Filing Icon  
10/22/2021Alex C. LevitInsiderBuy3,000$5.00$15,000.00View SEC Filing Icon  
10/22/2021Martin A. LehrCEOBuy10,000$5.00$50,000.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Context Therapeutics (NASDAQ:CNTX)

22.82% of Context Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CNTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Context Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2022Jane Street Group LLC72,060$80K0.0%N/A0.451%Search for SEC Filing on Google Icon
11/15/2022State Street Corp32,907$37K0.0%+79.8%0.206%Search for SEC Filing on Google Icon
11/15/2022Two Sigma Investments LP56,531$63K0.0%N/A0.354%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.640,699$0.71M0.0%+1.9%4.013%Search for SEC Filing on Google Icon
11/15/2022Quadrature Capital Ltd45,889$51K0.0%N/A0.287%Search for SEC Filing on Google Icon
11/14/2022Worth Venture Partners LLC322,628$0.36M0.2%+8.4%2.021%Search for SEC Filing on Google Icon
11/14/2022Renaissance Technologies LLC130,588$0.15M0.0%N/A0.818%Search for SEC Filing on Google Icon
11/1/2022swisspartners Ltd.85,000$94K0.1%+101.3%0.532%Search for SEC Filing on Google Icon
8/15/2022State Street Corp18,300$39K0.0%N/A0.115%Search for SEC Filing on Google Icon
8/15/2022Atria Wealth Solutions Inc.24,000$51K0.0%N/A0.150%Search for SEC Filing on Google Icon
8/13/2022Virtu Financial LLC46,445$98K0.0%N/A0.291%Search for SEC Filing on Google Icon
8/12/2022Northern Trust Corp23,200$49K0.0%N/A0.145%Search for SEC Filing on Google Icon
8/12/2022Affinity Asset Advisors LLC883,654$1.87M0.8%+13.6%5.535%Search for SEC Filing on Google Icon
5/17/2022Worth Venture Partners LLC317,729$0.69M0.3%+81.6%1.990%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC20,309$44K0.0%-68.6%0.127%Search for SEC Filing on Google Icon
5/13/2022Affinity Asset Advisors LLC777,610$1.69M0.3%N/A4.870%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.236,279$0.51M0.0%+10.1%1.480%Search for SEC Filing on Google Icon
5/4/2022swisspartners Ltd.14,315$4.98M3.5%-66.1%0.090%Search for SEC Filing on Google Icon
2/14/2022Altium Capital Management LP493,531$1.31M0.4%N/A4.501%Search for SEC Filing on Google Icon
2/11/2022QCM Cayman Ltd.14,041$37K0.2%N/A0.128%Search for SEC Filing on Google Icon
2/10/2022AIGH Capital Management LLC762,721$2.03M0.6%N/A6.955%Search for SEC Filing on Google Icon
2/9/2022swisspartners Ltd.42,235$0.11M0.1%N/A0.385%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Context Therapeutics logo
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Read More on Context Therapeutics

Today's Range

Now: $1.38
Low: $1.33
High: $1.40

50 Day Range

MA: $1.19
Low: $1.02
High: $1.42

52 Week Range

Now: $1.38
Low: $0.95
High: $7.65

Volume

98,200 shs

Average Volume

348,794 shs

Market Capitalization

$22.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Who are the company insiders with the largest holdings of Context Therapeutics?

Context Therapeutics' top insider shareholders include:
  1. Martin A Lehr (CEO)
  2. Alex C Levit (Insider)
Learn More about top insider investors at Context Therapeutics.

Who are the major institutional investors of Context Therapeutics?

Context Therapeutics' top institutional shareholders include:
  1. Vanguard Group Inc. — 4.01%
  2. Worth Venture Partners LLC — 2.02%
  3. Renaissance Technologies LLC — 0.82%
  4. swisspartners Ltd. — 0.53%
  5. Jane Street Group LLC — 0.45%
  6. Two Sigma Investments LP — 0.35%
Learn More about top institutional investors of Context Therapeutics stock.

Which major investors are buying Context Therapeutics stock?

In the previous quarter, CNTX stock was acquired by institutional investors including:
  1. Renaissance Technologies LLC
  2. Jane Street Group LLC
  3. Two Sigma Investments LP
  4. Quadrature Capital Ltd
  5. swisspartners Ltd.
  6. Worth Venture Partners LLC
  7. State Street Corp
  8. Vanguard Group Inc.
Within the previous year, these company insiders have bought Context Therapeutics stock:
  1. Martin A Lehr (CEO)
  2. Alex C Levit (Insider)
Learn More investors buying Context Therapeutics stock.
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks”
Buy this small group of unique stocks… never sell them… and make all the money you need… No matter what happens in the market.

Revealed here: the name and ticker of the #1 stock.
>>>
pixel